Trial Profile
Phase Ib/II, open-label, multicenter, randomized trial to investigate the combination of entinostat and atezolizumab in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic breast cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Entinostat (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 12 Jan 2018 New trial record